{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-031470","form_type":"8-K/A","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.593139+00:00","generated_at":"2026-06-05T02:22:53.996897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Fennec pre-announces Q4 2023 net revenue ~$9.2-9.7M, up 41-49% QoQ","bullets":["Q4 2023 net revenue expected $9.2-9.7M, a 41-49% increase vs Q3 2023.","Full-year 2023 net revenue expected ~$20.7-21.2M.","Audited full-year results expected on or about March 26, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-031470","json":"https://secwatch.observer/filing/0001104659-24-031470.json","markdown":"https://secwatch.observer/filing/0001104659-24-031470.md","text":"https://secwatch.observer/filing/0001104659-24-031470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/tm248156d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:22:53.996897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10f2b04582b260813524dff80cb6d9e646c79e70","claim":"FENNEC PHARMACEUTICALS INC. reported Fourth quarter 2023 results: revenue approximately $9.2 to $9.7 million.","evidence_excerpt":"• Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter 2023"},{"label":"Revenue","value":"approximately $9.2 to $9.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"a0ea98e5768b77792de4215c05793cbf736f40ec","claim":"FENNEC PHARMACEUTICALS INC. reported Full-year 2023 results: revenue approximately $20.7 to $21.2 million.","evidence_excerpt":"• Full-year 2023 net revenues are expected to be approximately $20.7 to $21.2 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-year 2023"},{"label":"Revenue","value":"approximately $20.7 to $21.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}